300246.SZ
Guangdong Biolight Meditech Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 14.80
−1.79%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.1B | 1.1B | 1.1B | 1.2B | 1.2B |
| Cost of Revenue | 819.1M | 813.9M | 772.9M | 806.8M | 826.4M |
| Gross Profit | 271.5M | 281.5M | 287.6M | 387.2M | 357.3M |
| Operating Expenses | |||||
| R&D Expense | 68.6M | 69.7M | 76.9M | 85.8M | 87.5M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 109.3M | 109.6M | 119.9M | 99.6M | 100.3M |
| Selling & Marketing Expense | 130.5M | 129.8M | 142.1M | 155.3M | 163.5M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 345.0M | 339.9M | 356.7M | 351.0M | 364.6M |
| Cost and Expenses | 1.2B | 1.2B | 1.1B | 1.2B | 1.2B |
| Operating Income (EBIT) | (81.0M) | (64.7M) | (66.9M) | (26.1M) | 25.7M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (103.3M) | (76.3M) | (71.1M) | (46.2M) | 22.1M |
| Income Tax Expense | (13.7M) | (10.9M) | (1.1M) | 14.8M | (2.5M) |
| Bottom Line | |||||
| Net Income | (91.2M) | (69.4M) | (71.4M) | (65.2M) | 22.1M |
| Earnings from Cont. Ops | (89.6M) | (65.4M) | (70.0M) | (61.0M) | 24.6M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (91.2M) | (69.4M) | (71.4M) | (65.2M) | 22.1M |
| Per Share | |||||
| Basic EPS | (CN¥0.35) | (CN¥0.26) | (CN¥0.27) | (CN¥0.25) | CN¥0.08 |
| Diluted EPS | (CN¥0.35) | (CN¥0.26) | (CN¥0.27) | (CN¥0.25) | CN¥0.08 |
| Revenue Per Share | CN¥4.13 | CN¥4.14 | CN¥4.04 | CN¥4.52 | CN¥4.54 |
| Shares | |||||
| Basic Shares Outstanding | 264.2M | 264.6M | 262.6M | 263.9M | 260.7M |
| Diluted Shares Outstanding | 264.2M | 264.6M | 262.6M | 263.9M | 260.7M |
| Profitability Metrics | |||||
| EBITDA | — | 12.0M | 2.8M | 33.7M | 78.2M |
| D&A | — | 76.6M | 69.7M | 59.8M | 52.5M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026